Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
Lexaria Bioscience Corp. (LXX)
Lexaria Corp. has announced a name change to Lexaria Bioscience Corp.
Shares will begin trading under the new name on Thursday, May 12, 2016.
Disclosure documents are available www.thecse.com
Please note the CUSIP, ISIN and symbol will remain the same.
Effective Date: May 12, 2016
If you have any questions or require further information, please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com